ACT500

ACT500 (formerly known as NM6606) is an investigational oral small molecule drug being developed by Xiamen Amoytop Biotech for the treatment of non-alcoholic steatohepatitis (NASH), now commonly referred to as metabolic dysfunction-associated steatohepatitis (MASH). The drug is currently in Phase 1 clinical development in China, where it is being evaluated for safety, tolerability, and pharmacokinetics in healthy adult participants (NCT06893796). Formulated as a tablet for oral administration, ACT500 represents an expansion of Xiamen Amoytop Biotech's pipeline into the metabolic liver disease space. While its specific biological target has not been publicly disclosed in trial registries, its development for NASH suggests it may target metabolic or inflammatory pathways associated with hepatic fat accumulation and fibrosis.